Choose a language and wait for the translated text.
Shots:
Acadia has presented additional data from the P-II (RADIANT) trial of once-daily remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) at CTAD 2026, building on the previously reported topline results
At wk.6, the 60 mg dose was favored over placebo on CGI-I-ADP at wks. 2, 4 and 6 (nominal p=0.0232, 0.0082 and 0.0208), with 44.0% of patients improved or very much improved vs 31.8% on placebo; NPI/NPI-NH psychosis score change was -7.3 vs -5.9 (nominal p=0.0385), while the primary endpoint (SAPS-H+D, -2.2 points) narrowly missed (p=0.0603)
TEAEs occurred in 36.8% vs 41.7% on placebo, with similar serious AE and discontinuation rates; there were no deaths in either remlifanserin arm and Acadia continues the P-III portion of the RADIANT program
Ref: Business Wire | Image: Acadia | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026 appeared first on PharmaShots.